登录

SPH Health Commerce Raises ¥1.033M in Series B Financing

作者: Mailman 2021-02-24 14:09
三诺生物
http://www.sinocare.com
企业数据由 动脉橙 提供支持
快速检测慢性疾病产品研发、生产、销售商 | IPO后其它轮次 | 运营中
中国-湖南
2013-01-01
水木创投
查看

(VCBeat) Feb. 18, 2021 -- Shanghai Pharma ("SPH") announced recently that the "Internet +" pharmaceutical commerce platform -- SPH Health Commerce Co., Ltd. ("SPH Health") has raised 1.033 billion yuan in a Series B funding round on January 18. The transaction is the first large financing in China's healthcare sector in 2021.


Established on March 18, 2015, SPH Health Commerce is an "Internet +" medical business technology platform of SPH.


The latest round was co-led by Shanghai Biomedical Industry Fund and China Jianyin Investment, with participation from Sinocare, Shanghai Trust, New Alliance Capital, Ample Harvest Finance, and Huadong Industrial Group. 


At the same time as the latest round, SPH Health Commerce has also completed the acquisition and integration of Guangzhou Baizhou New & Special Pharmaceutical and Kangdele Big Pharmacy. Meanwhile, it started the integration of its beside-hospital pharmacies and DTP brands. Combined with the original DTP pharmacy network and commercial innovation, SPH Health Commerce will accelerate the innovation of medication services in the whole life cycle on the basis of professional pharmacies, and the "Internet+" service of chronic disease medication based on electronic prescription and online pharmacies.


>>>>

About Shanghai Biomedical Fund


Shanghai Biomedical Fund is a municipal industrial fund approved by the Shanghai Municipal People's Government and initiated by Shanghai Industrial Investment, with a total targeting AUM of 50 billion yuan. It focuses on investments in biologics, innovative drugs, R&D outsourcing and services, medical devices and diagnostics, as well as innovative business models in the healthcare industry.


>>>>

About China Jianyin Investment (JIC)


JIC, established in 2004, is an integrated investment group. While committed to creating long-term and sustainable returns for the shareholders, JIC is keen on fulfilling corporate social responsibilities. The financial services, industrial manufacturing, culture, consumption and information technologies are among the sectors to which JIC attaches great importance.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】一块医药再次收获数千万美元融资,持续加码药房供应链创新和助力连锁化,赋能经营管理与人才优化

【首发】力美康完成2000万元pre-A轮融资,为连锁药店提供“人货场”全面赋能

叮当快药完成新一轮2.2亿美元融资 ,持续完善大健康开放生态、提供极致健康服务

Akang Health Raises ¥200M in Series B Funding Round Led by CICC Qide

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Guokang Health Raises ¥10M in Strategic Financing

2021-02-24
下一篇

Bioelectronica Secures Series A Funding from Proxima Ventures and Co-win Ventures

2021-02-24